These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38399440)

  • 1. Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening.
    Rao X; Qiao Z; Yang Y; Deng Y; Zhang Z; Yu X; Guo X
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening.
    Psilopatis I; Mantzari A; Vrettou K; Theocharis S
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics.
    Mandumpala JJ; Baby S; Tom AA; Godugu C; Shankaraiah N
    Life Sci; 2022 Mar; 292():120321. PubMed ID: 35031259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research.
    Bittman-Soto XS; Thomas ES; Ganshert ME; Mendez-Santacruz LL; Harrell JC
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting triple negative breast cancer with histone deacetylase inhibitors.
    Fedele P; Orlando L; Cinieri S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
    BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer Models.
    Smith JC; Husted S; Pilrose J; Ems-McClung SC; Stout JR; Carpenter RL; Walczak CE
    bioRxiv; 2023 Jun; ():. PubMed ID: 37397990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Bunnell BA; Martin EC; Burow ME; Collins-Burow BM
    Oncoscience; 2018 Mar; 5(3-4):99-108. PubMed ID: 29854878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
    Xiong N; Wu H; Yu Z
    Front Oncol; 2024; 14():1405491. PubMed ID: 38863622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
    Kurani H; Razavipour SF; Harikumar KB; Dunworth M; Ewald AJ; Nasir A; Pearson G; Van Booven D; Zhou Z; Azzam D; Wahlestedt C; Slingerland J
    Clin Cancer Res; 2022 May; 28(9):1948-1965. PubMed ID: 35135840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
    Bauer JA; Ye F; Marshall CB; Lehmann BD; Pendleton CS; Shyr Y; Arteaga CL; Pietenpol JA
    Breast Cancer Res; 2010; 12(3):R41. PubMed ID: 20576088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review.
    Muhammad A; Forcados GE; Katsayal BS; Bako RS; Aminu S; Sadiq IZ; Abubakar MB; Yusuf AP; Malami I; Faruk M; Ibrahim S; Pase PA; Ahmed S; Abubakar IB; Abubakar M; Yates C
    Epigenomics; 2022 Jun; 14(11):711-726. PubMed ID: 35473304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.